Online inquiry

IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13657MR)

This product GTTS-WQ13657MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13657MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10338MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ1136MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ12375MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ11725MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ15330MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ7083MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ14701MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ1267MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-414
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW